Breast Cancer Research and Treatment

, Volume 125, Issue 2, pp 431–439

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

  • Joanne L. Blum
  • Joseph Kohles
  • Edward McKenna
  • Nana Scotto
  • Sylvia Hu
  • Dawn Odom
  • James A. Kaye
  • Stefan Glück
Clinical trial

Abstract

We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500–2,510 mg/m2/day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34%) were 18–49 years old, 246 (43%) were 50–64, and 131 (23%) were ≥65. Median average daily dose was 2,067 mg/m2 in the 18- to 49-year-old group and 2,105 mg/m2 in the 50–64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71–0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50%) patients experienced progressive disease, while 114 (20%) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8%), 85 (34.6%), and 59 (45.0%) patients in the 18–49, 50–64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.

Keywords

Metastatic breast cancer Capecitabine Chemotherapy Clinical trial Age Tolerability 

References

  1. 1.
    U.S. Centers for Disease Control and Prevention: Breast cancer rates by age. http://www.cdc.gov/cancer/breast/statistics/age.htm
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 598:225–249CrossRefGoogle Scholar
  3. 3.
    Anderson WF, Jatoi I, Sherman ME (2009) Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol 27:5308–5311CrossRefPubMedGoogle Scholar
  4. 4.
    Christman K, Muss HB, Case LD, Stanley V (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 268:57–62CrossRefPubMedGoogle Scholar
  5. 5.
    Pentheroudakis G, Fountzilas G, Kalofonos HP, Hellenic Cooperative Oncology Group et al (2008) Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 66:237–247CrossRefPubMedGoogle Scholar
  6. 6.
    Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 25:3699–3704CrossRefPubMedGoogle Scholar
  7. 7.
    Sledge GW, Robert N, Sparano JA et al (1995) Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 22(3 Suppl 6):105–108PubMedGoogle Scholar
  8. 8.
    Xeloda® (capecitabine) [prescribing information]: Genentech, Inc. South San Francisco, CA; 2009Google Scholar
  9. 9.
    Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592CrossRefPubMedGoogle Scholar
  10. 10.
    Stockler M, Sourjina T, Grimison P et al (2007) A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 25:39s (18S; abstr 1031)Google Scholar
  11. 11.
    O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823CrossRefPubMedGoogle Scholar
  12. 12.
    Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMedGoogle Scholar
  13. 13.
    Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768CrossRefPubMedGoogle Scholar
  14. 14.
    Talbot DC, Moiseyenko V, Van Belle S et al (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367–1372CrossRefPubMedGoogle Scholar
  15. 15.
    O’Shaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247–1254CrossRefGoogle Scholar
  16. 16.
    Balducci L (2001) The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8(Suppl 2):1–25PubMedGoogle Scholar
  17. 17.
    Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN (1996) Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 156:882–888CrossRefPubMedGoogle Scholar
  18. 18.
    Muss HB, Berry DA, Cirrincione CT et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055–2065CrossRefPubMedGoogle Scholar
  19. 19.
    Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116:1234–1242CrossRefPubMedGoogle Scholar
  20. 20.
    Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792–2798CrossRefPubMedGoogle Scholar
  21. 21.
    Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545–553CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Joanne L. Blum
    • 1
  • Joseph Kohles
    • 2
  • Edward McKenna
    • 2
  • Nana Scotto
    • 3
  • Sylvia Hu
    • 2
  • Dawn Odom
    • 4
  • James A. Kaye
    • 4
  • Stefan Glück
    • 5
  1. 1.Baylor-Sammons Cancer Center, Texas OncologyUS OncologyDallasUSA
  2. 2.Roche Laboratories, IncNutleyUSA
  3. 3.F. Hoffman-LaRocheBaselSwitzerland
  4. 4.RTI Health SolutionsResearch Triangle ParkUSA
  5. 5.Sylvester Comprehensive Cancer CenterUniversity of Miami School of MedicineMiamiUSA

Personalised recommendations